Rigel Pharmaceuticals (RIGL) Capital Expenditures (2010 - 2023)

Rigel Pharmaceuticals' Capital Expenditures history runs 14 years deep, the most recent figure standing at $29000.0 for Q4 2023.

• In Q4 2023, Capital Expenditures fell 96.91% year-over-year to $29000.0; the TTM figure through Dec 2023 stood at -$56000.0 (down 112.44% YoY), while the FY2023 annual figure was -$56000.0, down 112.44% from the prior year.
• Capital Expenditures for Q4 2023 stood at $29000.0, up from $14000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $1.5 million in Q4 2019, with the low at -$678000.0 in Q3 2022.
• The 5-year median for Capital Expenditures is $6500.0 (2023), against an average of $163050.0.
• Peak annual rise in Capital Expenditures reached 10216.67% in 2020, while the deepest fall reached 3962.5% in 2020.
• Rigel Pharmaceuticals' Capital Expenditures stood at $1.5 million in 2019, then fell by 23.88% to $1.1 million in 2020, then sank by 143.76% to -$498000.0 in 2021, then jumped by 288.76% to $940000.0 in 2022, then sank by 96.91% to $29000.0 in 2023.
• Business Quant data shows RIGL's Capital Expenditures at $29000.0 in Q4 2023, $14000.0 in Q3 2023, and -$1000.0 in Q2 2023.